Navigation Links
Savient Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/10/2009

2008 -------- -------- -------- -------- Revenues: Product sales, net $679 $315 $1,764 $1,459 Other revenues 1 38 4 82 -------- -------- -------- -------- 680 353 1,768 1,541 -------- -------- -------- -------- Cost and expenses: Cost of goods sold 372 219 863 552 Research and development 11,638 15,726 24,401 26,887 Selling, general and administrative 7,397 10,450 16,865 19,714 -------- -------- -------- -------- 19,407 26,395 42,129 47,153 -------- -------- -------- -------- Operating loss (18,727) (26,042) (40,361) (45,612) Investment income (expense), net (27) 411 (229) 1,364 Other expense, net (36,055) (162) (36,168) (312) -------- -------- -------- -------- Loss before income taxes (54,809) (25,793) (76,758) (44,560) Income tax benefit - (1,595) - (2,810) -------- -------- -------- -------- Net loss $(54,809) $(24,198) $(76,758) $(41,750) ======== ======== ======== ======== Loss per common share: Basic and diluted $(0.92) $(0.45) $(1.35) $(0.78) ====== ====== ====== ====== Weighted-average number of common and commo
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed incident ... incident cases in 2013 to 11,568 diagnosed incident cases ... 4.35%, during the forecast period. In 2023, the US ... of aGVHD in the 6MM, with 4,989 diagnosed incident ... diagnosed incident cases of aGVHD, with 704 diagnosed incident ...
(Date:7/13/2014)... decreased ability to identify odors might indicate the ... examinations of the eye could indicate the build-up ... the brain, according to the results of four ... International Conference 2014 (AAIC 2014) in Copenhagen. , ... to identify odors was significantly associated with loss ...
(Date:7/13/2014)... Wright & Schulte LLC has learned ... in July of 2015, in U.S. District Court, District ... the discovery process in the South Carolina federal ... over the multidistrict litigation (MDL). The complaints pending in ... who allege that they took the statin medication to ...
(Date:7/13/2014)... Hills, California (PRWEB) July 13, 2014 ... Danny Musico has formed a promotional partnership with Aqua ... plant based Omega-3 EPA supplement . The collaboration ... is a celebrity fitness trainer , actor, model, ... Hollywood’s go-to trainer for A-List celebrities, he has prepared ...
(Date:7/13/2014)... July 13, 2014 Hope Palliative & Hospice ... grief support group at the Tamarack Senior Living Community in ... at 10:30 A.M. on the 3rd Wednesdays of every month. ... at the Tamarack Community located at 55 S. Greeley St. ... individuals and there is no cost for the group. ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... undertake a long-term weight training program produce more ... physiologists //to understand why weight training improves muscle ... study published in the December issue of the ... different forms of growth hormone, used different testing ...
... found that young women who grow up in cities or move ... ,Princess Diana was known to suffer from this eating ... country, and moved to London as a teenager. ,Bulimia ... a routine of over-eating and vomiting or purging. This study ...
... researchers have discovered a protein interaction that may explain ... findings, published in and featured on the cover of ... the mutated Huntington’s protein interacts with another protein to ... , ,“Cholesterol is essential for promoting the connection ...
... issue of Human Gene Therapy has published the findings ... to treat erectile dysfunction.// The finding shows that gene ... gene therapy is beneficial for months, and hence could ... ,Lead author Arnold Melman, M.D., professor and ...
... told that patients undergoing chemotherapy in remote areas may be ... patient sending a text of his symptoms according to their ... of a red alert sent to medical staff, or an ... new age technology may be used along with a mobile ...
... is always the case that women would have to work ... be it in career or otherwise. This was recently reiterated ... of Physiology-Endocrinology and Metabolism”. ,According to this ... of growth hormone by women whereas men use testosterone for ...
Cached Medicine News:Health News:Varying Weight Training Intensity Ups Growth Hormone in Women 2Health News:Link Between Huntington’s and Abnormal Cholesterol Levels in Brain Establishe 2Health News:Gene Therapy May Be the Solution for Erectile Dysfunction 2
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 20, 2011 Ann Arbor SPARK recently celebrated the conclusion ... and a reception.  At the Ann Arbor SPARK Boot Camp ... Boot Camp" winner, based on the quality of its investor ... engagement though the Ann Arbor SPARK Business Accelerator.   ...
... HYDERABAD, India, May 20, 2011 Neuland Laboratories Ltd., ... (APIs), complex intermediates, and contract research and manufacturing services ... results for the 2011 fiscal year (FY) ended March ... report that in fiscal year 2011, Neuland delivered on ...
Cached Medicine Technology:Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp 2Neuland Labs Reports Financial Results for Fiscal Year 2011 2
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
Inquire...
... Immunosorbent Assays(ELISA) is intended for the detection ... Measles Rubeola) virus in human sera. Individual ... determination of immune status. Paired sera, acute ... or a significant rise in antibody as ...
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
Medicine Products: